This presentation will cover recent cardiovascular trials, device development and protocol changes.
1. Discuss strategies for primary and secondary risk prevention
2. Understand recent study data regarding PCSK9 inhibitors and NOACs for prevention
3. Understand the background for indications for TAVR and LAA occluders as well as technical considerations during implantation
|Primary Care Cardiovascular Update (2.5 MB)||34 Pages||Available after Purchase|
Dr. Anthony Agostini is a board certified interventional Cardiologist and has been practicing in Amarillo since June of 2007. He is a graduate of Penn State University and attended medical school at Lake Erie College of Osteopathic Medicine. Dr. Agostini completed both his Cardiology and Interventional Cardiology Fellowship at Temple University School of Medicine in Pittsburgh, PA. Prior to joining the Cardiology Center of Amarillo, Dr. Agostini was in private practice in Longview, Texas.
Please wait ...